XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.4

SEGMENT INFORMATION (Tables)

3 Months Ended

Jan. 31, 2026

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

 SCHEDULE OF SEGMENT INFORMATION

		Cancer Vaccines				CAR-T Therapies				Other				Total				Cancer Vaccines				CAR-T Therapies				Other				Total
		For the three months ended January 31,
		2026																2025
		Cancer Vaccines				CAR-T Therapies				Other				Total				Cancer Vaccines				CAR-T Therapies				Other				Total
Revenues		$	-			$	-			$	-			$	-			$	-			$	-			$	-			$	-
Research and development expenses			673				429				-				1,102				975				577				-				1,552
General and administrative expenses			989				622				3				1,614				1,152				663				19				1,834
Total operating expenses			1,662				1,051				3				2,716				2,127				1,240				19				3,386
Loss from operations			(1,662	)			(1,051	)			(3	)			(2,716	)			(2,127	)			(1,240	)			(19	)			(3,386	)
Interest income			80				51				-				131				109				63				1				173
Net loss		$	(1,582	)		$	(1,000	)		$	(3	)		$	(2,585	)		$	(2,018	)		$	(1,177	)		$	(18	)		$	(3,213	)
Total operating expenses		$	1,662			$	1,051			$	3			$	2,716			$	2,127			$	1,240			$	19			$	3,386
Less non-cash stock-based compensation			(488	)			(308	)			-				(796	)			(660	)			(392	)			(3	)			(1,055	)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)		$	1,174			$	743			$	3			$	1,920			$	1,467			$	848			$	16			$	2,331

		January 31, 2026				October 31, 2025
Total assets:
Cancer Vaccines		$	9,288			$	9,604
CAR-T Therapeutics			5,894				6,347
Other			51				129
Total		$	15,233			$	16,080
Total assets		$	15,233			$	16,080

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration